ATE291921T1 - Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta - Google Patents

Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta

Info

Publication number
ATE291921T1
ATE291921T1 AT00110056T AT00110056T ATE291921T1 AT E291921 T1 ATE291921 T1 AT E291921T1 AT 00110056 T AT00110056 T AT 00110056T AT 00110056 T AT00110056 T AT 00110056T AT E291921 T1 ATE291921 T1 AT E291921T1
Authority
AT
Austria
Prior art keywords
osteogenesis imperfecta
bisphosphonates
stage
bisphosphonate
treat
Prior art date
Application number
AT00110056T
Other languages
English (en)
Inventor
Emilio J A Roldan
Lloret Anibal Perez
Original Assignee
Gador Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP990102331A external-priority patent/AR018611A1/es
Application filed by Gador Sa filed Critical Gador Sa
Application granted granted Critical
Publication of ATE291921T1 publication Critical patent/ATE291921T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00110056T 1999-05-12 2000-05-12 Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta ATE291921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP990102331A AR018611A1 (es) 1999-05-12 1999-05-12 Un procedimiento aplicable a preparaciones medicas de bisfosfonatos y sus formulaciones, para el tratamiento de la osteogenesis imperfecta
US09/570,275 US6864228B1 (en) 1999-05-12 2000-05-12 Use of bisphosphonates for the treatment of osteogenesis imperfecta

Publications (1)

Publication Number Publication Date
ATE291921T1 true ATE291921T1 (de) 2005-04-15

Family

ID=36190412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00110056T ATE291921T1 (de) 1999-05-12 2000-05-12 Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta

Country Status (5)

Country Link
US (3) US6864228B1 (de)
EP (1) EP1051976B1 (de)
AT (1) ATE291921T1 (de)
CA (1) CA2308532C (de)
ES (1) ES2238950T3 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
HU228400B1 (en) 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
ES2192136B1 (es) * 2002-01-04 2005-03-16 Italfarmaco, S.A. Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
CN1939314A (zh) 2002-05-10 2007-04-04 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
SI1596870T2 (sl) 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
WO2007070972A1 (en) * 2005-12-22 2007-06-28 Synergy Thermal Technologies Pty Ltd An air conditioning assembly
CN101711359A (zh) * 2007-05-18 2010-05-19 麦迪美特控股有限公司 用于测量液体内分析物浓度的带插头的测试芯片、用于测试芯片的外壳和用于插头的插座
EA032327B1 (ru) * 2013-03-20 2019-05-31 Джензим Корпорейшн Способы лечения несовершенного остеогенеза

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta

Also Published As

Publication number Publication date
EP1051976A2 (de) 2000-11-15
EP1051976A3 (de) 2002-10-23
EP1051976B1 (de) 2005-03-30
US20050026870A1 (en) 2005-02-03
US20080227756A1 (en) 2008-09-18
CA2308532A1 (en) 2000-11-12
US6864228B1 (en) 2005-03-08
US7846474B2 (en) 2010-12-07
ES2238950T3 (es) 2005-09-16
CA2308532C (en) 2005-11-29

Similar Documents

Publication Publication Date Title
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
ATE251903T1 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
EP1233770A4 (de) Phosphonatverbindungen
ATE394103T1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
ATE376444T1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
ATE291921T1 (de) Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE60028253D1 (de) Neue purine
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DK0994884T3 (da) Diphosphonsyresalte til behandling af osteoporose
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
NO20043113L (no) Fremgangsmate for behandling av benforstyrrelse
DE50010972D1 (de) UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN
DE50200626D1 (de) Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen
DE50105384D1 (de) Zubereitung zur behandlung von flächigen, offenen wunden
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties